Physician profile
Michael J Murray
NPI 1154344877
$3,058.80
in general payments reported to CMS, 2019-2025
35 companies · $566 in 2025
The $566 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $735 · 2020: $277 · 2021: $190 · 2022: $329 · 2023: $297 · 2024: $664 · 2025: $566.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,528.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,527.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $531.88 | 2019-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Pfizer INC. | $522.43 | 2019-2025 | |
| Novo Nordisk INC | $324.04 | 2019-2025 | Ozempic, Rybelsus |
| Novartis Pharmaceuticals Corporation | $146.62 | 2019-2020 | |
| Abbvie INC. | $132.74 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $127.76 | 2019-2025 | Airsupra |
| Phathom Pharmaceuticals, INC. | $121.53 | 2024 | Voquezna |
| Amgen INC. | $108.84 | 2019-2025 | Evenity, Prolia, Otezla |
| Abbott Laboratories | $106.84 | 2023-2025 | Freestyle Libre 3 |
| Genzyme Corporation | $97.68 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $84.98 | 2021-2024 | Camzyos, Eliquis |
| Sumitomo Pharma America, INC. | $75.71 | 2025 | Gemtesa |
| Lilly USA, LLC | $75.06 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Allergan, INC. | $66.40 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $52.77 | 2019-2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $52.18 | 2022-2024 | Veozah |
| Exact Sciences Corporation | $50.88 | 2024-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.07 | 2019-2020 | |
| Daiichi Sankyo INC. | $33.08 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $31.22 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $29.31 | 2021-2022 | |
| Csl Behring | $28.41 | 2020-2024 | Haegarda |
| Biogen, INC. | $25.22 | 2024 | Leqembi |
| Eisai INC. | $24.24 | 2024 | |
| Inspire Medical Systems, INC. | $19.23 | 2024 | Inspire |
| Biohaven Pharmaceutical Holding Company LTD. | $18.55 | 2022 | |
| Supernus Pharmaceuticals, INC. | $18.18 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $16.96 | 2024 | Rexulti |
| Radius Health, INC. | $16.91 | 2020 | |
| Idorsia Pharmaceuticals US INC | $16.12 | 2023 | Quviviq |
| Merck Sharp & Dohme LLC | $15.30 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.56 | 2022 | |
| Philips North America LLC | $12.36 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.58 | 2019 | |
| Sanofi-Aventis U.S. LLC | $11.16 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Murray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.